The "Ewing Sarcoma Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, …
Agenus ... Celldex's vaccine failure was one of 2016's worst: Rintega performed as expected, but the control group receiving standard chemo did unusually well. It looks like the heavy losses left bruises that the market isn't ready to …
A month has gone by since the last earnings report for Celldex Therapeutics, Inc. CLDX. Shares have lost about 4.4% in that time frame, underperforming the market. Will the recent negative trend continue leading up to the stock's next …
Celldex Therapeutics (NASDAQ: CLDX) saw its stock take a huge nosedive in 2016. That's what happens when your lead product flops in a late-stage clinical study. Did anything go right for the company this year? Actually, yes. Here's …
General and administrative spend declined 4.9% to $7.8 million, reflecting lower commercial planning costs, partially offset by higher stock-based compensation expense. Celldex is currently conducting a phase IIb study on glembatumumab …
It looks like the heavy losses left bruises that the market isn't ready to forget, and the stock has yet to recover. That could change before too long. Celldex has another candidate approaching the finish line, called glemba, that is entirely …
Celldex Therapeutics, Inc. CLDX is expected to report third-quarter 2016 results on Nov 3. Celldex’s performance has been encouraging with a three-quarter average positive surprise of 4.85%. In the last reported quarter, the company …